Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 163 -1.51%
22 May 9:33 a.m.
sparc.life BSE: 532872 NSE: SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE
  • Market Cap ₹ 5,304 Cr.
  • Current Price ₹ 163
  • High / Low ₹ 258 / 109
  • Stock P/E
  • Book Value ₹ -6.69
  • Dividend Yield 0.00 %
  • ROCE -279 %
  • ROE %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -3.42%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Miscellaneous

Part of BSE 500 BSE Healthcare BSE SmallCap BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
48 24 21 14 17 17 13 15 27
137 126 113 116 122 110 116 89 80
Operating Profit -90 -102 -91 -103 -106 -93 -103 -74 -53
OPM % -188% -427% -432% -740% -639% -555% -800% -494% -196%
11 10 8 6 4 2 0 0 0
Interest 0 0 0 0 1 1 1 3 5
Depreciation 3 3 3 3 3 3 3 3 3
Profit before tax -82 -95 -86 -100 -105 -96 -107 -79 -61
Tax % 0% 0% 0% 0% 0% 0% 0% 0% -1%
-82 -95 -86 -100 -106 -96 -107 -80 -60
EPS in Rs -2.53 -2.94 -2.66 -3.07 -3.26 -2.96 -3.31 -2.45 -1.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
239 76 72
453 478 395
Operating Profit -214 -402 -323
OPM % -90% -532% -450%
11 29 2
Interest 8 2 9
Depreciation 12 13 12
Profit before tax -223 -387 -343
Tax % 0% 0% -0%
-223 -387 -343
EPS in Rs -6.86 -11.93 -10.55
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -5%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 12%
Stock Price CAGR
10 Years: -9%
5 Years: 5%
3 Years: -9%
1 Year: -22%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Equity Capital 32 32 32
Reserves 480 93 -249
16 61 269
302 328 284
Total Liabilities 830 515 336
106 108 152
CWIP 27 44 1
Investments 291 2 0
406 362 183
Total Assets 830 515 336

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
-69 -429 -360
-548 392 158
617 42 199
Net Cash Flow -1 5 -3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Debtor Days 50 75 82
Inventory Days 0
Days Payable
Cash Conversion Cycle 50 75 82
Working Capital Days -189 -494 -956
ROCE % -108% -279%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.09% 69.09% 68.23% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68%
2.40% 2.38% 3.48% 3.64% 3.64% 3.67% 3.30% 3.24% 2.64% 2.15% 2.23% 1.45%
0.76% 0.76% 0.76% 0.63% 0.63% 0.65% 0.67% 0.67% 0.17% 0.21% 0.64% 1.13%
27.75% 27.77% 27.53% 30.04% 30.06% 29.99% 30.36% 30.41% 31.51% 31.96% 31.47% 31.76%
No. of Shareholders 94,49493,71896,33798,7771,00,8071,01,4331,03,9901,02,7431,25,1841,28,2051,31,0341,42,864

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls